H.C. Wainwright analyst Vernon Bernardino initiated coverage of Candel Therapeutics with a Buy rating and $11 price target. The analyst looks for the company’s December 2022 catalysts to be "near-term value inflection points." He is bullish on the ability of Candel’s multifactorial virus-based vector discovery platform, enLIGHTEN, to create novel therapies that activate tumor-killing mechanisms in the tumor microenvironment.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CADL:
- Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
- Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
- Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
- Candel Therapeutics presents data on CAN-2409 in combination with nivolumab
- Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights